Samsung Galaxy Book Hands-On – Best 2-in-1 Windows Tablet Yet?

Samsung Galaxy Book – the TabPro S's Replacement

A few days after its local launch (July 29), I was able to spend some time with the Samsung Galaxy Book. Huge thanks to Samsung for lending me one!

After failing to do a live unboxing/initial impressions video, I decided to just do a short hands-on with the live demo unit that I was lent. And I have to say, this is the best Windows 10 2-in-1 tablet that I have tried so far.

Quick comparison between TabPro S and Galaxy Book.

Putting it in the leagues of the iPad Pro 10.5 and the Samsung Galaxy Tab S3 would be unjust. But considering my experiences with those two, I couldn't help but compare.

For related content, check these out:

So, for whom is the Samsung Galaxy Book?

If any, I see it as something that Windows-dependent professionals on the go would prefer to bring on a daily basis. Being 8.9mm thin and 648g heavy in bare, it isn't too much to bring everyday. With the included keyboard cover, S-Pen, and multiport adapter out of the box, the PhP 44,990/USD 900 price tag felt a little bit justified on my end. Considering original Samsung SRP, I can't help but notice how huge the difference is with the base m3, 4GB RAM and 128GB internal storage variant.

I understood the pricing meant that it would go against Microsoft's Surface Pro 4 that goes for PhP 54.9k/USD 1100 (7th Gen i5, 4GB RAM, 128 GB Internal), the single 7th Gen core m3 variant felt a little bit offish. I kind of hoped that they brought in an i5 variant instead.

How it like?

As an ultraportable 2-in-1 tablet, it's pretty handy. Over the weekend, I was able to bring it with me. With its heft and center of mass, I wouldn't recommend to hold it as a thinner and lighter tablet. Trying to watch anime while on the bus was a bit unsettling. On a plane though, it's going to be an entirely different story.

Display

The display, despite being a TFT LCD felt nice to watch and type on with the scaling being perfect for its 1920×1280 resolution. FHD content was meant for this, and I have yet to try 4K.

Performance

Unlike its full-on Android tablet counterpart, this was more of a productivity tablet with its Windows 10 OS out-of-the-box. Doing office work on it is a breeze, thanks to the dual-core Intel Core m3 that runs at 1.0GHz (up to 2.6GHz Turbo Boost) and is thankfully hyperthreaded.

While many may find the 4GB of DDR3 RAM (which I believe is LPDDR3-1866), it kept up with my transitions between word processing and web browsing. Lag was virtually absent in the entire weekend that I spent with it.

Using Krita x64 on it was more than satisfying because of the 4096 pressure points of the included S-Pen. I'm no digital artist, but it was fun drawing whatever came to mind. I initially thought that the Intel HD 615 wouldn't be enough, but I have yet to test its limits in graphics processing.

Speakers

As I've said, this is meant to be a productivity station. The stereo speakers didn't do our music justice. Personally, I have no complaints or whatsoever since I usually listen/watch with my earphones or over-ears on.

Battery

Its 4000mAh battery is advertised to last for 9 hours – and I'm starting to believe Samsung. I topped it off this Saturday before heading into a cosplay event and haven't charged it ever since. In my estimation, I have used it actively for about 6 hours already. The fact that there's still about 20% left in the battery and that in itself is amazing.

Keyboard

Typing on a chiclet keyboard has been a regular thing for me as of late since I don't have enough desk space to accommodate my tenkeyless whenever I'm at home. Thing is, the spacing and the 1.5mm travel distance feels pretty nice. The tactility the provided keyboard cover provides is respectable so far.

(Initial) Final Thoughts

All purposes and intents considered, I'm starting to lean more towards the iPad Pro 10.5 because of its responsiveness. Furthermore, the only Windows-dependent programs I use for work are video editing software. I may have to spend PhP 7500/USD 150 or so for a keyboard and Apple Pencil, but the total pricing will still be around the same.

Stay tuned for I will make sure to test every nook and cranny of this little wonder. Expect a full review next week!

SPECS Samsung Galaxy Book Display [1920×1280]10.6-inch TFT LCD Display, Size 261.112 x 179.07 x 8.89 mm, 648 g Design Metal body Colors Silver Chipset Intel Processor Intel Core m3-7Y30 1.0GHz (up to 2.6GHz Turbo Boost), HT Graphics Intel HD615 Memory 4GB RAM + 64GB/128GB eMMC Front camera 5 MP, f/2.2 Connectivity WiFi ac, Bt 4.1, NFC, GPS, GLONASS OS Windows 10 Battery Non-removable 4,000mAh Ports USB 3.1 Type-C 1.0, 3.5mm headphone jack Official Price PhP 44,990 Availability date July 28, 2017 Where to buy Samsung stores and authorized retailers

Related

Source: Samsung Galaxy Book Hands-On – Best 2-in-1 Windows Tablet Yet?

Group Mobile Supplying Tablets for McElroy’s New DataLogger® 6

Group Mobile working with McElroy on the recently released new DataLogger© 6, an Android-powered tablet solution that simplifies collecting and analyzing data on fusible pipeline projects

Chandler, AZ (PRWEB) July 27, 2017

Group Mobile, a rapidly-expanding, premier provider of innovative, full-service mobile technology solutions, is pleased to announce that it is supplying the ruggedized, Android-powered tablets that interface with McElroy's newly-released DataLogger® 6. McElroy is the leading manufacturer of thermoplastic pipe fusion equipment and accessories.

Significant orders for the fully-customizable Getac ZX70 are anticipated in the second half of 2017 and throughout 2018. The DataLogger 6 is loaded with new features that make collecting and analyzing data on fusible pipeline projects easier than ever before. The device offers a modernized touchscreen and easy-to-navigate software system with on-screen instructions. Fusion operators are guided through each step of the fusion process to ensure that pipe joints were fused with the correct pressures and heating times.

"Group Mobile is proud to work with McElroy in bringing this quality assurance tool for pipeline validation to the industry," said Darin White, President of Group Mobile. "This order represents the first wave of devices designed for a growing market that fuses pipe under the supported standards. With the release of the DataLogger 6, we continue to ensure that our customers receive market-leading, innovative and cost-effective mobile technology solutions."

The Getac ZX70's ergonomic, one-handed design coupled with an HD touchscreen enhances readability and is water and dust resistant to further improve productivity and efficiency even in the toughest work environments. The ZX70 is highly customizable with an open-source operating system, making this tablet well-known for its simplicity and energy-saving capabilities.

About Group Mobile

Group Mobile, a wholly owned subsidiary of Form Holdings, headquartered in Phoenix, AZ, serves customers world-wide. Group Mobile is a rapidly expanding and growing and innovative full end-to-end solution provider of rugged mobile hardware, lifecycle services, system integration, hardware service support, pre-and post-deployment, break-fix, warranty repair, customer support helpdesk and more — all constructed to solve pressing problems and ensure our customers are receiving exceptional value, return on investment and a trusted long-lasting partnership. Group Mobile has mastered the true challenges of mobility through understanding the key elements required for a successful mobile deployment — hardware, connectivity, data and customer back-end network infrastructures. Visit http://www.groupmobile.com for more information.

About McElroy Inc.

McElroy is the leading manufacturer and innovator in the science of joining thermoplastic pipe. The Tulsa, Okla.-based company offers the industry's most complete line of pipe fusion equipment and quality assurance accessories that increase quality, productivity and efficiency on the jobsite. For more than 60 years, McElroy has successfully demonstrated a complete dedication to excellence that lies at the heart of the design, engineering and manufacturing of its products. For additional information, please visit the McElroy website at http://www.mcelroy.com.

About FORM Holdings Corp.

FORM Holdings Corp. (Nasdaq: FH) is a publicly held diversified holding company that specializes in identifying, investing in and developing companies with superior growth potential. FORM's current holdings include XpresSpa, Group Mobile, FLI Charge, Infomedia and intellectual property assets. XpresSpa is the world's largest airport spa company. Group Mobile is a provider of rugged, mobile and field-use computing products, serving customers worldwide. FLI Charge designs, develops, licenses, manufactures and markets wireless conductive power and charging solutions. Infomedia is a leading provider of customer relationship management and monetization technologies to mobile carriers and device manufacturers. FORM Holdings' intellectual property division is engaged in the development and monetization of intellectual property. To learn more about FORM Holdings Corp. http://www.FormHoldings.com

Forward-Looking Statements

This press release includes forward-looking statements, which may be identified by words such as "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Statements in this press release regarding the merger between FORM and XpresSpa; XpresSpa's projected revenue, the ability to raise capital to fund operations and business plan; the continued listing of FORM's securities on the Nasdaq Capital Market; market acceptance of FORM products; the collective ability to protect intellectual property rights; competition from other providers and products; FORM's management and board of directors after the merger; and any o ther statements about FORM's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to: FORM's inability to maintain the listing of its securities on the Nasdaq Capital Market; the potential lack of market acceptance of FORM's products; FORM's inability to monetize and recoup FORM's investment with respect to assets and other businesses that that were acquired or will be acquired in the future; general economic conditions and level of information technology and consumer electronics spending; unexpected trends in the mobile phone and telecom computing industries; the potential loss of one or more of FORM's significant Original Equipment Manufacturer ("OEM") suppliers, t he potential lack of market acceptance of FORM's products; market acceptance, quality, pricing, availability and useful life of FORM's products and services, as well as the mix of FORM's products and services sold; potential competition from other providers and products; FORM's inability to license and monetize FORM's patents, including the outcome of litigation; FORM's inability to develop and introduce new products and/or develop new intellectual property; FORM's inability to protect FORM's intellectual property rights; new legislation, regulations or court rulings related to enforcing patents, that could harm FORM's business and operating results; FORM's inability to retain key members of its management team; and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including FORM's Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 30, 2017. FORM exp ressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

FORM Holdings

Jeff Sonnek

ICR

646-277-1263

Jeff.Sonnek(at)icrinc.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/07/prweb14542432.htm

Source: Group Mobile Supplying Tablets for McElroy's New DataLogger® 6

Best Place To Buy! Viagra Tablet

Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension.

Package

Price

Per Pills

Savings

Order

25 mg x 10 pills

$18.99

$1.90

$0.00

25 mg x 20 pills

$29.99

$1.50

$8.00

25 mg x 30 pills

$37.99

$1.27

$18.90

25 mg x 60 pills

$68.99

$1.15

$45.00

25 mg x 90 pills

$92.99

$1.03

$78.30

25 mg x 120 pills

$105.99

$0.88

$122.40

25 mg x 180 pills

$134.99

$0.75

$207.00

25 mg x 360 pills

$148.99

$0.41

$536.40

25 mg x 270 pills

$171.99

$0.64

$340.20

Package

Price

Per Pills

Savings

Order

50 mg x 10 pills

$25.99

$2.60

$0.00

50 mg x 20 pills

$40.99

$2.05

$11.00

50 mg x 30 pills

$52.99

$1.77

$24.90

50 mg x 60 pills

$89.99

$1.50

$66.00

50 mg x 90 pills

$120.99

$1.34

$113.40

50 mg x 120 pills

$127.99

$1.07

$183.60

50 mg x 180 pills

$151.99

$0.84

$316.80

50 mg x 270 pills

$191.99

$0.71

$510.30

50 mg x 360 pills

$224.99

$0.62

$712.80

Package

Price

Per Pills

Savings

Order

100 mg x 10 pills

$28.99

$2.90

$0.00

100 mg x 20 pills

$45.99

$2.30

$12.00

100 mg x 30 pills

$55.99

$1.87

$30.90

100 mg x 60 pills

$99.99

$1.67

$73.80

100 mg x 90 pills

$133.99

$1.49

$126.90

100 mg x 120 pills

$156.99

$1.31

$190.80

100 mg x 180 pills

$211.99

$1.18

$309.60

100 mg x 270 pills

$286.99

$1.06

$496.80

100 mg x 360 pills

$343.99

$0.96

$698.40

Package

Price

Per Pills

Savings

Order

120 mg x 10 pills

$29.99

$3.00

$0.00

120 mg x 20 pills

$47.99

$2.40

$12.00

120 mg x 30 pills

$60.99

$2.03

$29.10

120 mg x 60 pills

$109.99

$1.83

$70.20

120 mg x 90 pills

$148.99

$1.66

$120.60

120 mg x 120 pills

$177.99

$1.48

$182.40

120 mg x 180 pills

$240.99

$1.34

$298.80

120 mg x 270 pills

$324.99

$1.20

$486.00

120 mg x 360 pills

$389.99

$1.08

$691.20

Package

Price

Per Pills

Savings

Order

130 mg x 10 pills

$32.99

$3.30

$0.00

130 mg x 20 pills

$49.99

$2.50

$16.00

130 mg x 30 pills

$62.99

$2.10

$36.00

130 mg x 60 pills

$113.99

$1.90

$84.00

130 mg x 90 pills

$152.99

$1.70

$144.00

130 mg x 120 pills

$183.99

$1.53

$212.40

130 mg x 180 pills

$247.99

$1.38

$345.60

130 mg x 270 pills

$334.99

$1.24

$556.20

130 mg x 360 pills

$389.99

$1.08

$799.20

Package

Price

Per Pills

Savings

Order

150 mg x 10 pills

$34.99

$3.50

$0.00

150 mg x 20 pills

$51.99

$2.60

$18.00

150 mg x 30 pills

$65.99

$2.20

$39.00

150 mg x 60 pills

$118.99

$1.98

$91.20

150 mg x 90 pills

$160.99

$1.79

$153.90

150 mg x 120 pills

$192.99

$1.61

$226.80

150 mg x 180 pills

$260.99

$1.45

$369.00

150 mg x 270 pills

$351.99

$1.30

$594.00

150 mg x 360 pills

$401.99

$1.12

$856.80

Package

Price

Per Pills

Savings

Order

200 mg x 10 pills

$40.99

$4.10

$0.00

200 mg x 20 pills

$61.99

$3.10

$20.00

200 mg x 30 pills

$77.99

$2.60

$45.00

200 mg x 60 pills

$140.99

$2.35

$105.00

200 mg x 90 pills

$190.99

$2.12

$178.20

200 mg x 120 pills

$228.99

$1.91

$262.80

200 mg x 180 pills

$308.99

$1.72

$428.40

200 mg x 270 pills

$416.99

$1.54

$691.20

200 mg x 360 pills

$499.99

$1.39

$975.60

Product Description

Common useThe main component of Viagra is Sildenafil Citrate.Sildenafil Citrate affects the response to sexual stimulation. It acts by enhancing smooth muscle relaxation using nitric oxide, a chemical that is normally released in response to sexual stimulation. This smooth muscle relaxation allows increased blood flow into certain areas of the penis, which leads to an erection.Sildenafil Citrate is applied for the treatment of erectile dysfunction (impotence) in men and pulmonary arterial hypertension.Sildenafil Citrate may also be used for other purposes not listed above.

Dosage and directionUsually the recommended dose is 50 mg. It is taken approximately 0,5-1 hour before sexual activity. Do not take Viagra more then once a day.A high fat meal may delay the time of the effect of this drug.Try not to eat grapefruit or drink grapefruit juice while you are being treated with Sildenafil Citrate .

PrecautionsBefore you start taking Sildenafil Citrate , tell your doctor or pharma cist if you are allergic to it; or if you have any other allergies.Aged people may be more sensitive to the side effects of the drug.

ContraindicationsViagra is contraindicated in patients taking another medicine to treat impotence or using a nitrate drug for chest pain or heart problems.This medicine should not be taken by women and children as well as in patients with a known hypersensitivity to any component of the tablet.

Possible side effectThe most common side effects are headache, flushing, heartburn, stomach upset, nasal stuffiness, lightheadedness, dizziness or diarrhea.A serious allergic reaction to this drug is very rare, but seek immediate medical help if it occurs.Many people using this medicine do not have serious side effects.In case you notice any side effects not listed above, contact your doctor or pharmacist.

Drug interactionThis drug should not be used with nitrates and recreational drugs called "poppers" containing amyl or butyl nitrite; alpha- blocker medications; other medications for impotence; high blood pressure medicines, etc.Consult your doctor or pharmacist for more details.

Missed doseViagra is used as needed, so you are unlikely to be on a dosing schedule.

OverdoseIf you think you have used too much of this medicine seek emergency medical attention right away. The symptoms of overdose usually include chest pain, nausea, irregular heartbeat, and feeling light-headed or fainting.

StorageStore your medicines at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store the drugs in the bathroom. Keep all drugs away from reach of children and pets.

DisclaimerWe provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Source: Best Place To Buy! Viagra Tablet

WarehouseOS Tablet Technology for Warehouse Management Instead of RF Guns

This press release was orginally distributed by SBWire

Salt Lake City, UT -- (SBWIRE) -- 07/27/2017 -- Warehouse Mobile Solutions, makers of WarehouseOS, are making a strong movement to tablets as the preferred mechanism in materials handling. Warehouse Mobile Solutions tablet technology for warehouse management was recently featured in an article titled, "Productivity in the Warehouse Accomplished by Eliminating the RF Guns and Moving to Tablet Technology," in Automation & Controls Today magazine.

According to manufacturing journalist TR Cutler, "When it comes to productivity in the warehouse, too often plant managers and distribution center managers confuse how software and scanners impact the time it takes to fulfill customer orders. Having employees tethered to cumbersome hand-held terminals while trying to key in information on a small, hard-to-read screen prevents maximized picking rates and optimal order accuracy."

New solutions are moving away from the RF guns and are demonstrating double picking rates after only 10 minutes of training with enclosures mounted to mobile picking carts. The company recently completed the installation of its Tablet Directed, Barcode/Order Fulfillment Solution, at Hot Shots Distributing located in Charlotte, North Carolina. For nearly two decades the company has been supplying the fiery food industry with over 1,400 fiery products. Utilizing the latest version of WarehouseOS, Version 2.0, fully integrated with Hot Shots ERP system, order fulfillment, and inventory management are now a paperless process.

Automation & Controls Today magazine reaches the global manufacturing and industrial community. The media company is a well-respected international business-to-business media organization that specializes in both print and online media coverage.

To read the entire article, go to: http://bit.ly/1XAMz8c

About WarehouseOSThe RF gun, constant verifications, small keypads, and hard to read screens are quickly becoming yesterday's technology. Tablets are replacing the RF gun. WarehouseOS, a new tablet-based Warehouse Operations System brings warehouses into the future today. Warehouse management systems have been around for a long time with too many companies still using the RF gun to conduct inventory management, scan in new items, and pick orders. The RF gun solutions typically cost double what modern solutions offer. WarehouseOS and associated apps have been developed to make everything about the warehouse easier and better. Apps allow small or large companies to receive products, manage inventory, perform cycle counting, conduct single picks or do batch picking, verify items picked and pack them into boxes.

An easy to navigate user interface means warehouse personnel need almost no training before performing warehouse tasks. Receiving, put-away, picking, and packaging quickly become the easiest jobs on the floor. A team of experts in material handling equipment and solutions developed WarehouseOS to maximize the throughput of warehousing and distributing facilities. From small eCommerce, to high volume SKU facilities, from omni-channel companies to FMCG (fast moving consumer goods), WarehouseOS is equipped to handle everything. From small startups with simple needs to complex, large distribution centers, WarehouseOS is the table solution which enables manufacturers and distribution centers to be a step ahead of the competition.

Learn more at http://www.warehousemobilesolutions.com and follow on Twitter @WarehouseOS.

For more information on this press release visit: http://www.sbwire.com/press-releases/warehouseos-tablet-technology-for-warehouse-management-instead-of-rf-guns-839224.htm

Source: WarehouseOS Tablet Technology for Warehouse Management Instead of RF Guns

Zydus receives final approval from USFDA for Mesalamine Delayed -Release Tablets, 800 mg

Zydus Cadila has received the final approval from the USFDA for Mesalamine Delayed-Release Tablets in the strength of 800 mg. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.

The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.544.3 as compared to the previous close of Rs. 531.65. The total number of shares traded during the day was 211567 in over 4277 trades.

The stock hit an intraday high of Rs. 554.2 and intraday low of 531.1. The net turnover during the day was Rs. 115167485.

Source: Zydus receives final approval from USFDA for Mesalamine Delayed -Release Tablets, 800 mg

Orally Disintegrating Tablet Market Analysis and Value Forecast Snapshot 2025

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 07/24/2017 -- Drug delivery systems are becoming progressively sophisticated as pharmaceutical researchers obtain a good understanding of the biochemical and physiological parameters pertinent to their performance. The drug delivery through oral route is the standard technique in the pharmaceutical industry as it is considered as the most economic, convenient, and safest route of drug administration. The oral tablets are usually taken with water only with an exclusion of orally disintegrating tablets and chewing tablets. The oral tablets are released into the gastrointestinal tract and they are quickly absorbed into the blood circulation. Orally disintegrating tablet is a solid dosage form that quickly disintegrates or dissolves in the mouth within one minute and does not require water for swallowing.

Read the Comprehensive Overview of Orally Disintegrating Tablet Market: http://www.transparencymarketresearch.com/orally-disintegrating-tablet-market.html

Orally disintegrating tablets are becoming a choice of alternative for conventional tablets or capsules. The first orally disintegrating tablet was approved in 1996. Orally disintegrating tablets are known by many names such as fast dissolving, orodispersible, mouth-dissolving, and quick disintegrating tablets. They are uncoated tablets and they dispersed fast and are quickly absorbed. These tablets are intended to break down quickly in the mouth and the active pharmaceutical ingredients are absorbed in the gastrointestinal tract. They have been developed for various indications such as mental illness, migraine, and many other chronic medical conditions.

There are various methods available to develop orally disintegrating tablets such as tablet molding, freeze frying or lyophilization, spray drying, phase transition, mass-extrusion, cotton candy technology, direct compression method, and sublimation. The direct compression method is the most preferred method for manufacturing of orally disintegrating tablet as it provides adequate structural integrity and is cost effective in nature.

The global orally disintegrating tablet market is segmented on the basis of disease indication, distribution channel, and geography. On the basis of disease indication, the market is segmented into gastrointestinal diseases, central nervous system (CNS) diseases, oncology, and others. The CNS diseases segment is expected to gain high share of the market during the forecast period owing to increasing prevalence of CNS diseases such as depression, migraine, Parkinson's disease, Alzheimer's disease, and schizophrenia. Other than CNS diseases, the gastrointestinal diseases segment is expected to expand at a high CAGR during the forecast period. On the basis of distribution channel, the global market is segmented into hospital pharmacy, retail pharmacy, drug store, and online pharmacy.

Geographically, the global market for orally disintegrating tablet is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to register a high market share during the forecast period owing to increasing acceptance for technologically advanced products as well as rising prevalence of CNS diseases. Asia Pacific and Middle East & Africa are expected to expand at high CAGRs during the forecast period owing to low cost of orally disintegrating tablets and rise in awareness about various dosage form of tablet.

Tablets and capsules have certain limitations such as bitter taste, swallowing discomfort, and large size, especially for geriatric patients and children. These limitations of tablets and capsules are major driving factors for the orally disintegrating tablet market. In addition, rise in adoption of compliant dosage form and better taste have significantly increased the demand for orally disintegrating tablets, which is expected to drive the market growth during the forecast period.

However, there are hurdles in formulation of relatively high dose for orally disintegrating tablets. The difficulty level is high for the formulation of an orally disintegrating tablet with dose of 500 mg. Thus, the dose of a tablet is limited to 400 mg or less.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24086

Key players operating in the global orally disintegrating tablet market include Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca, GlaxoSmithKline plc, Johnson & Johnson Services, F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Mission Pharmacal Company, and Sciele Pharma among others.

About TMRTransparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For more information on this press release visit: http://www.sbwire.com/press-releases/orally-disintegrating-tablet/release-838019.htm

Source: Orally Disintegrating Tablet Market Analysis and Value Forecast Snapshot 2025

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

CARY, N.C. (July 21, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.'s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

"We are pleased to be part of the distribution network for NERLYNX, as this promising agent provides oncologists a new treatment option for HER2-positive patients who remain at significant risk for disease recurrence after targeted therapy," said Brandon Tom, vice president, Biopharma Services, McKesson Specialty Health. "As prospects are poor for HER2-positive patients whose disease returns, any therapy that reduces the risk of recurrence is a welcome addition to the treatment options."

The most common adverse reactions associated with NERLYNX (≥5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decrease and urinary tract infection.

Biologics' oncology specialty pharmacy is recognized across the industry for its high-touch care model that supports patients with a multidisciplinary care team throughout the patient's cancer journey. Working together on behalf of the patient, the care team develops an individualized care plan that addresses the unique clinical, financial and emotional needs of each patient, streamlining communication back to the treating provider while empowering high-quality care. Each team includes a pharmacist with in-depth knowledge of oncology pharmaceuticals, an experienced oncology nurse who understands the unique clinical and psychosocial needs of cancer patients, and a financial counselor who is familiar with various financial assistance programs and organizations available to help cancer patients. The goal of this unique support system and patient-centric care model is to drive optimal outcomes and help ensure the best possible patient experience.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

Please click for Full Prescribing Information, including Patient Information. For additional IMPORTANT SAFETY INFORMATION, visit www.NERLYNX.com.

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient's best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.

Source: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

Best Online! Viagra Tablets In India

Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension.

Package

Price

Per Pills

Savings

Order

25 mg x 10 pills

$18.99

$1.90

$0.00

25 mg x 20 pills

$29.99

$1.50

$8.00

25 mg x 30 pills

$37.99

$1.27

$18.90

25 mg x 60 pills

$68.99

$1.15

$45.00

25 mg x 90 pills

$92.99

$1.03

$78.30

25 mg x 120 pills

$105.99

$0.88

$122.40

25 mg x 180 pills

$134.99

$0.75

$207.00

25 mg x 360 pills

$148.99

$0.41

$536.40

25 mg x 270 pills

$171.99

$0.64

$340.20

Package

Price

Per Pills

Savings

Order

50 mg x 10 pills

$25.99

$2.60

$0.00

50 mg x 20 pills

$40.99

$2.05

$11.00

50 mg x 30 pills

$52.99

$1.77

$24.90

50 mg x 60 pills

$89.99

$1.50

$66.00

50 mg x 90 pills

$120.99

$1.34

$113.40

50 mg x 120 pills

$127.99

$1.07

$183.60

50 mg x 180 pills

$151.99

$0.84

$316.80

50 mg x 270 pills

$191.99

$0.71

$510.30

50 mg x 360 pills

$224.99

$0.62

$712.80

Package

Price

Per Pills

Savings

Order

100 mg x 10 pills

$28.99

$2.90

$0.00

100 mg x 20 pills

$45.99

$2.30

$12.00

100 mg x 30 pills

$55.99

$1.87

$30.90

100 mg x 60 pills

$99.99

$1.67

$73.80

100 mg x 90 pills

$133.99

$1.49

$126.90

100 mg x 120 pills

$156.99

$1.31

$190.80

100 mg x 180 pills

$211.99

$1.18

$309.60

100 mg x 270 pills

$286.99

$1.06

$496.80

100 mg x 360 pills

$343.99

$0.96

$698.40

Package

Price

Per Pills

Savings

Order

120 mg x 10 pills

$29.99

$3.00

$0.00

120 mg x 20 pills

$47.99

$2.40

$12.00

120 mg x 30 pills

$60.99

$2.03

$29.10

120 mg x 60 pills

$109.99

$1.83

$70.20

120 mg x 90 pills

$148.99

$1.66

$120.60

120 mg x 120 pills

$177.99

$1.48

$182.40

120 mg x 180 pills

$240.99

$1.34

$298.80

120 mg x 270 pills

$324.99

$1.20

$486.00

120 mg x 360 pills

$389.99

$1.08

$691.20

Package

Price

Per Pills

Savings

Order

130 mg x 10 pills

$32.99

$3.30

$0.00

130 mg x 20 pills

$49.99

$2.50

$16.00

130 mg x 30 pills

$62.99

$2.10

$36.00

130 mg x 60 pills

$113.99

$1.90

$84.00

130 mg x 90 pills

$152.99

$1.70

$144.00

130 mg x 120 pills

$183.99

$1.53

$212.40

130 mg x 180 pills

$247.99

$1.38

$345.60

130 mg x 270 pills

$334.99

$1.24

$556.20

130 mg x 360 pills

$389.99

$1.08

$799.20

Package

Price

Per Pills

Savings

Order

150 mg x 10 pills

$34.99

$3.50

$0.00

150 mg x 20 pills

$51.99

$2.60

$18.00

150 mg x 30 pills

$65.99

$2.20

$39.00

150 mg x 60 pills

$118.99

$1.98

$91.20

150 mg x 90 pills

$160.99

$1.79

$153.90

150 mg x 120 pills

$192.99

$1.61

$226.80

150 mg x 180 pills

$260.99

$1.45

$369.00

150 mg x 270 pills

$351.99

$1.30

$594.00

150 mg x 360 pills

$401.99

$1.12

$856.80

Package

Price

Per Pills

Savings

Order

200 mg x 10 pills

$40.99

$4.10

$0.00

200 mg x 20 pills

$61.99

$3.10

$20.00

200 mg x 30 pills

$77.99

$2.60

$45.00

200 mg x 60 pills

$140.99

$2.35

$105.00

200 mg x 90 pills

$190.99

$2.12

$178.20

200 mg x 120 pills

$228.99

$1.91

$262.80

200 mg x 180 pills

$308.99

$1.72

$428.40

200 mg x 270 pills

$416.99

$1.54

$691.20

200 mg x 360 pills

$499.99

$1.39

$975.60

Product Description

Common useThe main component of Viagra is Sildenafil Citrate.Sildenafil Citrate affects the response to sexual stimulation. It acts by enhancing smooth muscle relaxation using nitric oxide, a chemical that is normally released in response to sexual stimulation. This smooth muscle relaxation allows increased blood flow into certain areas of the penis, which leads to an erection.Sildenafil Citrate is applied for the treatment of erectile dysfunction (impotence) in men and pulmonary arterial hypertension.Sildenafil Citrate may also be used for other purposes not listed above.

Dosage and directionUsually the recommended dose is 50 mg. It is taken approximately 0,5-1 hour before sexual activity. Do not take Viagra more then once a day.A high fat meal may delay the time of the effect of this drug.Try not to eat grapefruit or drink grapefruit juice while you are being treated with Sildenafil Citrate .

PrecautionsBefore you start taking Sildenafil Citrate , tell your doctor or pharma cist if you are allergic to it; or if you have any other allergies.Aged people may be more sensitive to the side effects of the drug.

ContraindicationsViagra is contraindicated in patients taking another medicine to treat impotence or using a nitrate drug for chest pain or heart problems.This medicine should not be taken by women and children as well as in patients with a known hypersensitivity to any component of the tablet.

Possible side effectThe most common side effects are headache, flushing, heartburn, stomach upset, nasal stuffiness, lightheadedness, dizziness or diarrhea.A serious allergic reaction to this drug is very rare, but seek immediate medical help if it occurs.Many people using this medicine do not have serious side effects.In case you notice any side effects not listed above, contact your doctor or pharmacist.

Drug interactionThis drug should not be used with nitrates and recreational drugs called "poppers" containing amyl or butyl nitrite; alpha- blocker medications; other medications for impotence; high blood pressure medicines, etc.Consult your doctor or pharmacist for more details.

Missed doseViagra is used as needed, so you are unlikely to be on a dosing schedule.

OverdoseIf you think you have used too much of this medicine seek emergency medical attention right away. The symptoms of overdose usually include chest pain, nausea, irregular heartbeat, and feeling light-headed or fainting.

StorageStore your medicines at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store the drugs in the bathroom. Keep all drugs away from reach of children and pets.

DisclaimerWe provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Source: Best Online! Viagra Tablets In India

Janssen Receives Positive CHMP Opinion for SYMTUZA The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet

Beerse, Belgium, 21 July 2017 – Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR).

If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantages of a STR coupled with the high genetic barrier to resistance that darunavir offers.

"Darunavir is one of the most widely used HIV treatments in the European Union due to its ability to control the HIV virus while offering a high barrier to resistance. We will now be able to combine a complete darunavir-based HIV treatment regimen into a once daily tablet. We are extremely excited to be one step closer to getting this therapy to people living with HIV and in doing so hope to reduce the treatment burden faced by many living with the virus," said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Janssen Infectious Diseases Therapeutics.

"A darunavir-based STR represents a significant evolution in treatment options for HIV patients," said Jean-Michel Molina, Professor of Infectious Diseases at the University of Paris Diderot. "With around two million people in Europe currently managing their HIV, this is a true advancement in helping patients achieve an undetectable viral load and improving quality of life. Reducing the pill burden allows people greater freedom and flexibility, and through this we may also improve treatment adherence."

The Positive Opinion is based on a bioequivalence study comparing the once-daily STR with the combined administration of the separate agents darunavir [D] 800 mg, cobicistat [C] 150 mg, and emtricitabine/tenofovir alafenamide [FTC/TAF] 200 mg/10 mg fixed-dose combination. A Phase 3 clinical trial programme investigating the efficacy and safety of the darunavir-based combination is underway. Data on the bioequivalence study, as well as interim data from the Phase 3 Pivotal EMERALD trial in virologically suppressed antiretroviral therapy (ART) experienced patients, who were switched to the STR, will be presented at the upcoming International AIDS Society (IAS) conference in Paris, France. Further EMERALD 48-week data, and 48-week data from the Phase 3 AMBER trial in ART naïve patients, will be released in due course. Please visit www.jnj.com/HIV for further details on the breadth of science being presented by Johnson & Johnson companies and its partners.

The CHMP's Positive Opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorisation for medicines in the European Economic Area. The European Commission's final decision is anticipated in the coming months.

Janssen have brought medicines to market across a range of patient populations that have helped to transform the efficacy and tolerability of treatment. Treatment regimens that combine D/C (REZOLSTA®, Janssen-Cilag International NV, U.S name PREZCOBIX®) and F/TAF (DESCOVY®, Gilead Sciences International Ltd) are currently approved[1],[2] for the treatment of HIV. SYMTUZA™ is a significant evolution of this approach, combining both treatments in a single, convenient tablet, and is part of Janssen's broader commitment to develop effective and innovative therapies which address the issues of adherence and resistance.

###

Notes to editorsOn 23 December 2014, Janssen and Gilead Sciences International Ltd amended a licensing agreement for the development and commercialisation of a once-daily STR combination of darunavir and Gilead's TAF, emtricitabine and cobicistat. Under the terms of the agreement, Janssen and its affiliates are responsible for the manufacturing, registration, distribution and commercialisation of this STR worldwide.

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea/ and follow us at .

About PREZISTA® (darunavir)PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.PREZISTA, co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.In deciding to initiate treatment with PREZISTA co-administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.

About REZOLSTA® (darunavir/cobicistat)REZOLSTA is an antiviral medicine used, in combination with other medicines, to treat adults with human immunodeficiency virus type 1 (HIV-1). REZOLSTA contains the active substances darunavir and cobicistat. The medicine is for use only in patients who have not received HIV treatment before or previously treated patients whose disease is not expected to be resistant to darunavir and who are healthy enough and have HIV virus levels below a certain threshold.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new indications and therapeutic combinations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product e fficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the year ended January 1, 2017, including under "Item 1A Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Source: Janssen Receives Positive CHMP Opinion for SYMTUZA The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Zydus launches Mesalamine Delayed Release Tablets in the US

Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2g in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda® and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ulcerative colitis which affects approximately 700,000 people within the US.

The group has received 26 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.544.25 as compared to the previous close of Rs. 524.95. The total number of shares traded during the day was 110480 in over 2674 trades.

The stock hit an intraday high of Rs. 549.55 and intraday low of 527.35. The net turnover during the day was Rs. 59462599.

Source: Zydus launches Mesalamine Delayed Release Tablets in the US

Xplore Offers Dramatically Increased Performance for Category-Leading 12” Rugged Tablet with New Intel® PCIe Solid State Drives

AUSTRALIA, Sydney, July 20, 2017 -- Xplore Technologies Corp. (NASDAQ:XPLR) and Intel Corporation (NASDAQ:INTC) today announced that the fastest rugged tablet available today, the Windows®-powered XSLATE R12, is gaining another significant boost in speed, power and storage capacity as Xplore becomes the first rugged tablet manufacturer to integrate Intel® PCIe Solid State Drives (SSD) into its portfolio. The performance-accelerating Intel PCIe SSDs are now shipping as a standard feature on all XSLATE R12 Intel Core® Series i7 models, including a new 1TB configuration option. The new drives deliver over 2X improvement in disk performance, and when combined with the i7 vPro processor, a 48% improvement in overall system performance*.

"Xplore is deeply committed to bringing the latest technology and innovation to our rugged mobile customers, and that is demonstrated once again with our new enhancements to the XSLATE R12," explained Brett Gross, ANZ Director Xplore. "Our long-standing technology collaboration with Intel is delivering improved productivity and performance to applications that require significant data storage and/or data processing, especially those used by manufacturers, utilities, first responders and field service organizations."

Some of the mobile workers who will immediately benefit from the Intel PCIe SSD-equipped XSLATE R12 include those who:

Opt not to store data in the cloud, either due to security concerns or application design, and instead need to store locally on the rugged tablet;

Frequently rely on data- and graphics-intensive applications, such as those used to generate 3D CAD drawings or GIS location intelligence; or

Have historically been forced to delete files to make room for the large amount of inspection, investigation or quality control photos and videos captured in a day's work.

"The Xplore XSLATE R12 with an Intel Core i7-7600U processor and an Intel 600p Series PCIe-based SSD is, by far, the fastest rugged tablet we have ever tested," noted Conrad H. Blickenstorfer, editor, RuggedPCReview.com. "It's amazing how Xplore's proactive adoption of leading edge technology is boosting rugged tablet performance to levels thought impossible just a short time ago."

The Intel-powered XSLATE R12 is prepared to multi-task in any demanding work environment, whether that be in hand or in a Secure Mobile Dock. It's equipped with pen and touch capabilities and backed by a Bluetooth™-connected keyboard that's always on call when needed to complete more data-intensive tasks. The standard hot-swappable battery is critical for long shifts while the large, outdoor-viewable display is protected by Corning® Gorilla Glass® for damage-resistant, day-and-night viewing. This highly flexible rugged tablet also features more connectivity options than others in its class, including antenna pass-through capabilities, an RJ-45 and True Serial port dongle, and a SlateMate barcode reader and HF RFID reader combo. The XSLATE R12 is available with multiple internal configurations, including a 7th generation Intel® Core™ i7 vPro processor with Windows® 10 and 6th generation Intel Core i5 with Windows 7, 8.1 or Windows 10.

For more information on the new XSLATE R12 rugged tablet lineup, please visit www.xploretech.com/XSLATER12.

*According to Passmark testing conducted in July 2017.

About Intel

Intel (NASDAQ:INTC) expands the boundaries of technology to make the most amazing experiences possible. Information about Intel can be found at newsroom.intel.com and intel.com.

About Xplore Technologies

Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors. The company's award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail. Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on Twitter, Facebook, LinkedIn, and YouTube.

Forward-Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

Source: Xplore Offers Dramatically Increased Performance for Category-Leading 12" Rugged Tablet with New Intel® PCIe Solid State Drives

Cadila's Mesalamine Delayed-Release Tablets launched in US

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Copyright © 2017 India Infoline Ltd. All rights Reserved.

India Infoline Limited (Formerly "India Infoline Distribution Company Limited"), CIN No.: U99999MH1996PLC132983, Corporate Office – IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel, Mumbai – 400013 Tel: (91-22) 4249 9000 .Fax: (91-22) 40609049, Regd. Office – IIFL House, Sun Infotech Park, Road No. 16V, Plot No. B-23, MIDC, Thane Industrial Area, Wagle Estate, Thane – 400604 Tel: (91-22) 25806650. Fax: (91-22) 25806654 E-mail: mail@indiainfoline.com Website: www.indiainfoline.com, Refer www.indiainfoline.com for detail of Associates.

National Stock Exchange of India Ltd. SEBI Regn. No. : INB231097537/ INF231097537/ INE231097537, Bombay Stock Exchange Ltd. SEBI Regn. No.:INB011097533/ INF011097533/ BSE-Currency, MCX Stock Exchange Ltd. SEBI Regn. No.: INB261097530/ INF261097530/ INE261097537, United Stock Exchange Ltd. SEBI Regn. No.: INE271097532, PMS SEBI Regn. No. INP000002213, IA SEBI Regn. No. INA000000623, SEBI RA Regn.: INH000000248

Source: Cadila's Mesalamine Delayed-Release Tablets launched in US

BRIEF-Impax reports FDA approval of its AB rated generic concerta extended-release tablets CII

July 17 (Reuters) - Impax Laboratories Inc:

* Impax announces FDA approval of its AB rated generic concerta® (methylphenidate hydrochloride) extended-release tablets CII

* Says don't anticipate sales of generic concerta to meaningfully impact earnings in 2017​

* Says ‍preparing for launch including working to secure api quota and currently expect to launch by end of this year​ Source text for Eikon: Further company coverage:

Source: BRIEF-Impax reports FDA approval of its AB rated generic concerta extended-release tablets CII

Wacom to release 24inch and 27inch cintiq pro tablets

Wacom has announced that they are going to be expanding their cintiq pro line by adding 24inch variant and a massive 32 inch variant. The 32inch tablet will be the biggest tablet that Wacom has ever created since the company was created in 1983. Both the new models will feature Wacom new pro pen 2 technology and will have 4K displays and no parallax. The new tablets will be released in January 2018 a year since Wacom released their smaller cintiq pro models.

The images of the new cintiq pro models shows that Wacom has opted to not to include a stand for the new models. This means Wacom has chosen to ignore customer complaints about wacom's cintiq 27qhd model not having a stand. This problem caused many using it to suffer from bad backs due to the poor drawing angle of the tablet meaning you had to slouch over the tablet for long periods. #cheapskates

The price of the new models is expected to be very steap with wacom stating that the new tablets will cost between £1,549 to £2,556. However with the various Chinese copycat tablets on the market and with the new 27inch dell canvas coming out this summer that has just about every feature that the new cintiq models have, it is surprising that Wacom still thinks that it can demand such a high price for their tablets. Wacom has however reduced the RRP of its other big tablets, reducing the 22HD Pen Display is dropping by £100 and the 27qhd and touch version will drop by £350.

This is good news for artists but bad news for their wallets.

Source: Wacom to release 24inch and 27inch cintiq pro tablets

Xiaomi Mi Max 2 Expected To Release in India on July 18

Xiaomi Mi Max 2 might be the company's next smartphone to come to India and the Chinese smartphone-maker has already started to tease it on social media. The second generation Mi Max comes with the iconic 6.44-inch Full HD display and a 5300mAh battery backing it up. The Indian release date of the Mi Max 2 is set for July 18.

Speaking of the upcoming handset, it is simply a giant. With a 6.44-inch screen, the Mi Max 2 will suffice your tablet needs. The phone comes with a full metal build and manages to look quite elegant.

Under the hood, the device is powered by the Snapdragon 625 SoC with eight Cortex-A53 cores clocked at 2.0 GHz. This is mated with 4 GB of RAM and 64 GB or 128 GB of onboard storage. The Mi Max 2 runs MIUI 8 based on Android 7.1.1 Nougat out of the box.

Coming to the optics, there is a 12 MP camera the back. It is powered by the flagship Sony IMX386 sensor. This is a significant improvement of the new Mi Max over the older one. For selfies, you will get a modest 5 MP unit.

Ads by Google

Connectivity-wise, the Mi Max 2 supports 4G LTE, VoLTE, VoWiFi, dual-band Wi-Fi, Bluetooth v4.2, GPS, A-GPS, BeiDou, etc. A huge 5300mAh battery juices up the phone and supports Qualcomm Quick Charge 3.0.

Xiaomi Mi Max 2 Specifications

6.44-inch Full HD (1080 x 1920) IPS Display

Snapdragon 625 SoC (8 x 2.0 GHz Cortex-A53)

Adreno 506 GPU

4 GB RAM and 64 / 128 GB Storage

12 MP Rear Camera + 5 MP Selfie Unit

MIUI 9 With Android 7.1.1 Nougat

4G LTE, VoLTE, dual-band Wi-Fi, Bluetooth v4.2

Type-C USB Port

5300mAh Battery

Xiaomi Mi Max 2 Availability and Pricing

The phablet is presumed to go on sale soon after releasing on 18th July. It will be available for purchase from Mi.com and some other online retailer. Regarding pricing, the 4 GB / 64 GB Mi Max 2 costs 1699 Yuan ($249 USD or Rs. 16,000 approx.) in China. Xiaomi is expected to price it similarly in India.

Source: Xiaomi Mi Max 2 Expected To Release in India on July 18

Xplore collaborates with Microsoft to accelerate Internet of Things solutions

Verified hardware and software enhance interoperability and allow faster time to production.

SYDNEY, AUSTRALIA - July 12, 2017 - Xplore Technologies Corp. (NASDAQ: XPLR), the Rugged Tablet Authority™, today announced it has joined Microsoft Azure Certified for Internet of Things (IoT), ensuring customers get IoT solutions up and running quickly with hardware and software that has been pre-tested and verified to work with Microsoft Azure IoT services. Microsoft Azure Certified for IoT allows businesses to reach customers where they are, working with an ecosystem of devices and platforms, allowing for faster time to production.

By certifying four of the company's popular rugged tablets – the XSLATE R12, the XSLATE B10, the Bobcat, and the F5m – to work with Microsoft Azure IoT services, Xplore is accelerating and simplifying the integration of rugged mobility solutions into today's industrial manufacturing and field applications. Xplore has been working with technology innovators such as Microsoft for more than 20 years to engineer rugged tablet-based mobility solutions that boast the right feature sets, workflow capabilities, and accessories for customers' current and future business needs. With Xplore's Windows-powered rugged tablets now Microsoft Azure Certified for IoT, it will be easy and quick for manufacturers, utilities, public safety agencies and other customers to deploy completely integrated mobile workforce solutions within their existing technology architectures.

"With the increased connectivity and digitalisation occurring across industries, the need for rugged mobility is only increasing. Xplore has always built our rugged tablets with customers' interoperability requirements in mind. They're meant to stay in the field for 3-5 years minimum. As such, we ensure our mobile computing platforms can connect to a host of operational technologies and specialty peripherals," said Brett Gross, ANZ Director of Xplore. "Microsoft Azure Certified for IoT validates Xplore's ability to jumpstart customers' IoT projects with pre-tested device and operating system combinations. We not only decrease the usual customisation and work required by other devices to achieve compatibility, but we accelerate customers' efficiency gains and overall mobility ROI when they deploy an Xplore Windows tablet."

"Microsoft Azure Certified for IoT extends our promise to bring IoT to business scale, starting with interoperable solutions from leading technology companies around the world," said Barb Edson, general manager for Data Platform and Internet of Things, Microsoft Corp. "With trusted offerings and verified partners, Microsoft Azure Certified for IoT accelerates the deployment of IoT even further."

IoT projects are complex and take a long time to implement. Customers find that choosing and connecting the right set of devices, assets or sensors to the cloud can be time-consuming. To jumpstart their IoT projects with confidence, customers are looking for certified devices and platforms that are tested for readiness, compatibility and usability with the Microsoft Azure IoT Suite. By choosing a partner from the Microsoft Azure Certified for IoT program, customers can save time and effort on project specs and RFP processes by knowing in advance what devices and offerings will work with the Azure IoT Suite.

Learn more about this collaboration at Azure Certified for IoT and explore the Azure IoT Suite today.

About Xplore Technologies

Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors. The company's award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail. Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on Twitter, Facebook, LinkedIn, and YouTube.

Forward Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

# # #

Source: Xplore collaborates with Microsoft to accelerate Internet of Things solutions

OpenL Tablets

'); }()); gptadRenderers['SF_ProjectSum_728x90_A'] = function(){ // jshint ignore:line googletag.cmd.push(function() { googletag.display('div-gpt-ad-1394209358853-0'); }); }; gptadRenderers['SF_ProjectSum_728x90_A'](); // jshint ignore:line } '); }()); gptadRenderers['SF_ProjectSum_HubIcon_200x90_A'] = function(){ // jshint ignore:line googletag.cmd.push(function() { googletag.display('div-gpt-ad-1394209358854-0'); }); }; gptadRenderers['SF_ProjectSum_HubIcon_200x90_A'](); // jshint ignore:line }
Source: OpenL Tablets

Vitacost Vitamin B12 Delayed Release -- 1000 mcg - 60 Tablets

Ask long-term raw food enthusiasts to explain the benefits of their diet, and they will gush about increased energy, mental clarity, a leaner body, clearer skin and a lower risk of disease. Not to mention that eating foods that don't come in packaging or require energy to cook is gentler on the environment. But what exactly is a raw food diet, and is it doable for everyone?

Like many prescriptive eating styles, there is a range of different raw food diets out there—everything from a fruit-only plan to one that incorporates raw eggs, unpasteurized dairy products and raw meats. However, the majority of raw foodists do not eat animal products, and their diets consist mainly of uncooked, unprocessed fruits, vegetables, nuts, seeds and grains—which have not been heated to more than 114 degrees Fahrenheit and have not been frozen.

"A food's natural enzymes are killed at 114 degrees," says Brigitte Mars, herbalist, raw food chef and author of Rawsome! (Basic Health Publications, 2004). "Heating food beyond that changes its chemical structure and robs it of its energy."

Whether a raw food's enzymes actually survive the journey from the stomach to the intestines is debatable, but Artturi Virtanen, a Nobel Prize-winning biochemist, did show that enzymes in uncooked vegetables are released in the mouth when chewed. These enzymes then work with others produced by the body to maximize the digestive process. And many raw food devotees believe that since this natural process of digesting mainly raw, vegetarian food is easier on the body and produces fewer toxins than cooked food, it can stave off both aging and disease.

The Science of Raw

There is no guarantee that eating raw fruits and vegetables will keep you from getting wrinkles, but according to a 2009 article in the journal Nutrition in Clinical Practice, it can reduce the risk of oral, pharyngeal, laryngeal, esophageal and gastric cancers. Even a few helpings a month of raw cruciferous vegetables such as cabbage, Brussels sprouts, broccoli and kale deliver enough cancer-fighting isothiocyanates to significantly lower the risk of bladder cancer, according to a 2008 article in Cancer Epidemiology, Biomarkers & Prevention. And a 2005 study in the Journal of Nutrition found that a strict raw food diet significantly lowers cholesterol and triglyceride levels.

There's no denying that a raw food regimen has a lot of checks in the "healthy" column: It's rich in fiber and antioxidants, low in sugar and usually devoid of alcohol and caffeine. But for a raw food diet to be completely healthy, it needs to be well thought-out—blueberry and date smoothies morning, noon and night won't provide all the necessary vitamins and minerals. In fact, getting adequate amounts of certain nutrients that generally come from animal products, such as vitamin B12, iron and calcium, can be a challenge. Taking supplements can help, as can loading up on vegetables rich in these nutrients.

"Leafy greens should be the foundation of the diet," says Mars, whose own diet is currently about 85 percent raw. "There was a time when I was eating over 95 percent raw, but I want to be able travel and eat at people's houses and not feel so restricted."

The key to success in any eating plan—raw food diet included—is to not restrict yourself so much that you feel frustrated and deprived. Simply adding more raw fruits and vegetables into your daily meals is a great way to ease into a raw food lifestyle. Play around with different techniques such as juicing, sprouting and dehydrating and see what works for you and your lifestyle. "There is no one way to do this; people should find what works for them," says Mars.

Source: Vitacost Vitamin B12 Delayed Release -- 1000 mcg - 60 Tablets

Industrial Tablet PC Market Trends and 2022 Forecast

(EMAILWIRE.COM, July 08, 2017 ) Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Industrial Tablet PC in these regions, from 2012 to 2022 (forecast), coveringUnited StatesEUChinaJapanSouth KoreaTaiwan

For more information about this report at http://www.reportsweb.com/global-industrial-tablet-pc-market-research-report-2017

Global Industrial Tablet PC market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players includingAdvantechGetacPanasonicZebraGlacier ComputerArchosAdlinkNexcomArbor TechnologyDAP TechnologiesXploreMobiledemandKontronOn the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split intoSmall Size (Less Than 11 Inches)Medium Size (11-17 Inches)Large Size (More Than 17 Inches)On the basis on the end users/applicat ions, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Industrial Tablet PC for each application, includingIndustrialTransportationHealthcareOther

Request a sample copy at http://www.reportsweb.com/inquiry&RW0001712184/sample

Table of Content1 Industrial Tablet PC Market Overview2 Global Industrial Tablet PC Market Competition by Manufacturers3 Global Industrial Tablet PC Production, Revenue (Value) by Region (2012-2017)4 Global Industrial Tablet PC Supply (Production), Consumption, Export, Import by Region (2012-2017)4.1 Global Industrial Tablet PC Consumption by Region (2012-2017)4.2 United States Industrial Tablet PC Production, Consumption, Export, Import (2012-2017)4.3 EU Industrial Tablet PC Production, Consumption, Export, Import (2012-2017)4.4 China Industrial Tablet PC Production, Consumption, Export, Import (2012-2017)4.5 Japan Industrial Tablet PC Production, Consumption, E xport, Import (2012-2017)4.6 South Korea Industrial Tablet PC Production, Consumption, Export, Import (2012-2017)4.7 Taiwan Industrial Tablet PC Production, Consumption, Export, Import (2012-2017)

5 Global Industrial Tablet PC Production, Revenue (Value), Price Trend by Type5.1 Global Industrial Tablet PC Production and Market Share by Type (2012-2017)5.2 Global Industrial Tablet PC Revenue and Market Share by Type (2012-2017)5.3 Global Industrial Tablet PC Price by Type (2012-2017)5.4 Global Industrial Tablet PC Production Growth by Type (2012-2017)

6 Global Industrial Tablet PC Market Analysis by Application6.1 Global Industrial Tablet PC Consumption and Market Share by Application (2012-2017)6.2 Global Industrial Tablet PC Consumption Growth Rate by Application (2012-2017)6.3 Market Drivers and Opportunities6.3.1 Potential Applications6.3.2 Emerging Markets/Countries

7 Global Industrial Tablet PC Manufacturers Profiles/Analysis7.1 Advantech7.1.1 Company Basic In formation, Manufacturing Base, Sales Area and Its Competitors7.1.2 Industrial Tablet PC Product Category, Application and Specification7.1.2.1 Product A7.1.2.2 Product B7.1.3 Advantech Industrial Tablet PC Capacity, Production, Revenue, Price and Gross Margin (2012-2017)7.1.4 Main Business/Business Overview7.2 Getac7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors7.2.2 Industrial Tablet PC Product Category, Application and Specification7.2.2.1 Product A7.2.2.2 Product B7.2.3 Getac Industrial Tablet PC Capacity, Production, Revenue, Price and Gross Margin (2012-2017)7.2.4 Main Business/Business Overview7.3 Panasonic7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors7.3.2 Industrial Tablet PC Product Category, Application and Specification7.3.2.1 Product A7.3.2.2 Product B7.3.3 Panasonic Industrial Tablet PC Capacity, Production, Revenue, Price and Gross Margin (2012-2017)7.3.4 Main Business/Business Overview8 Industria l Tablet PC Manufacturing Cost Analysis9 Industrial Chain, Sourcing Strategy and Downstream Buyers10 Marketing Strategy Analysis, Distributors/Traders11 Market Effect Factors Analysis12 Global Industrial Tablet PC Market Forecast (2017-2022)13 Research Findings and Conclusion

Purchase Complete Report at http://www.reportsweb.com/buy&RW0001712184/buy/2900. And get,Discount on report purchase at http://www.reportsweb.com/inquiry&RW0001712184/discount.

Source: Industrial Tablet PC Market Trends and 2022 Forecast

Buzzlogix Releases First Social Media Monitoring & Management App for Smartphones and Tablets

Buzzlogix Releases First Social Media Monitoring & Management App for Smartphones and Tablets

One of the leading all-in-one Social Media Monitoring, Management & Analytics Platforms is now available for all iOS and Android mobile devices.

Dallas, TX, July 07, 2017 --(PR.com)-- Buzzlogix today announced the release of its next generation all-in-one Social Media Monitoring, Analytics & Management solution for mobile devices.

The new Buzzlogix App provides Social Media Managers and Specialists with full fingertip access to their social media activities and campaigns from anywhere at any time. The app supports all features that normally can only be accessed from a PC workstation to be accessed from anywhere and at any time.

Buzzlogix Social Media Monitor & Manager for iOS

Buzzlogix Social Media Monitoring & Management Features

"Social Media Managers and Specialists need to understand and respond to social events at all times. With our free mobile app, we target those who need full control of their social media activities and events," explains Scott Sims, Buzzlogix CEO and co-founder.

Download the Free Buzzlogix Smartphone and Tablet Apps here:

Apple App Store (for iOS 8 or later )Google Play Store (for Android 4.4 or later)

Or find out more at https://buzzlogix.com/mobile-app

How Buzzlogix Social Media Monitoring & Management Works

Social Media Monitoring

Setup your topic streams with the user-friendly Wizard by adding your keywords, the channels and languages.

Buzzlogix instantly collects all the social media mentions from Facebook, Twitter, Instagram as well as blogs, news and discussions and many more from across the social web 24/7.

Buzzlogix then processes and enhances the data to display timelines and relevant reports on interactive dashboards.

Create your own comprehensive social media reports for export.Social Media Management

Logon with your social media accounts to manage them. Buzzlogix displays all accounts in one or multiple tabs in a side-by-side view. Receive and send messages from your social message inboxes. Post and schedule posts for your social accounts.

About Buzzlogix

Buzz logix is a smart and simple, all-in-one social media management, monitoring and engagement platform. Designed to empower social media specialists and people who need to work with social media on a day-to-day basis. Buzzlogix offers a comprehensive set of features to deliver effective social media management and monitoring. We believe that social media management and marketing should be simple, affordable and enable meaningful engagements. Using our cloud software platform and our mobile app generates stronger market insights, happier customers and leads to increased social media performance resulting in better services and sales. Buzzlogix is headquartered in Dallas, USA.(https://buzzlogix.com/contact)

Contact: Scott Sims at 166648@email4pr.com, +1 (800) 289-9644 or visit http://www.buzzlogix.com/

Source Buzzlogix LLC

Related Links

http://www.buzzlogix.com

Source: Buzzlogix Releases First Social Media Monitoring & Management App for Smartphones and Tablets

12-Inch Huawei MateBook E Pre-Orders For $799 In The US Before Release – Same Does D And X

We are pretty close to the official Huawei Matebook E release in the US now that it has started accepting pre-orders on Amazon. The 12-inch Windows 10 2-in-1 Huawei Matebook E have been taking orders internationally for 2 weeks already, but not nationally in the US with the correct MSRP of $799 before now:https://www.amazon.com/Huawei-MateBook-Graphics-Touchscreen-Titanium/

The same availability goes for the larger 13-inch Huawei MateBook X and the 15.6-inch Huawei MateBook D, although those two are laptops and not tablets.

Huawei MateBook E meanwhile is a tablet, or a 2-in-1 tablet with detachable keyboard cover. MateBook E was unveiled on May 23, and is the successor to the largely identical Huawei MateBook that was launched in the US in June last year.

There are 3 changes to the new 2017 model. The first one is the upgrade to a new 7th gen. Intel Core "Kaby Lake" processor, with options of Intel Core M3 7Y30 for $799 or Intel Core i5 7Y54 for $1000. The second change are the new Dolby Audio Premium stereo speakers, and finally, the third change is the much more practical keyboard cover that isn't as complicated as that of the predecessor, and even have tent mode now on the new model.

The other specs are that of an ultraslim 6.9mm tablet with a 12-inch screen sporting a 2160 x 1440 resolution display with 400 nits brightness and 85% color gamut, as well as active digitizer support for the optional $50 pen. RAM and storage are 4GB RAM and 128GB storage, or 8GB RAM and 256GB storage.

Huawei MateBook E has dual-band and dual-antenna 802.11 a/b/g/n/ac Wi-Fi, Bluetooth 4.1, a claimed 9 hour battery life from a 4430 mAh battery pack, a 5MP front camera, fingerprint reader, ambient light sensor, accelerometer, gyroscope, and a hall sensor. And this neat Windows 10 2-in-1 tablet has a USB Type-C port too.

As an ultraslim Windows 10 2-in-1 it is the most similar to the Samsung Galaxy Book 12, but on the specs and price side, it is also somewhat similar to the new entry level Surface Pro that was released on June 15. So it's nice to have options.

– Tom Bowen

Related Tablets: Huawei MediaPad T3 10 / Honor T3 10 Shipping ... Huawei MateBook E Taking Orders - Ultralight ... 8-Inch 4G LTE Android 7.0 Tablet Huawei Media... Huawei MediaPad M3 Lite 8.0 Specs Listed By R...
Source: 12-Inch Huawei MateBook E Pre-Orders For $799 In The US Before Release – Same Does D And X